# Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT

> **NCT05014594** · PHASE2 · UNKNOWN · sponsor: **Post Graduate Institute of Medical Education and Research, Chandigarh** · enrollment: 44 (estimated)

## Conditions studied

- Cirrhosis
- Ascites Hepatic

## Interventions

- **DRUG:** Dapagliflozin (10Mg Tab) along with standard medical therapy
- **DRUG:** Placebo of dapaglifozin along with standard medical therapy

## Key facts

- **NCT ID:** NCT05014594
- **Lead sponsor:** Post Graduate Institute of Medical Education and Research, Chandigarh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-03
- **Primary completion:** 2022-05-19
- **Final completion:** 2022-05-19
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2021-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05014594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05014594, "Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05014594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*